Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: A randomized trial

World Journal of Surgery

Volumn 20, Issue 5, 1996, Pages 521-527

  Das, S K ^a   Cohen, A T ^a   Edmondson, R A ^a   Melissari, E ^a   Kakkar, V V ^a  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHLEBOGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

AGED; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; THROMBOEMBOLISM; WARFARIN;

EID: 0030002495     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900081     Document Type: Article

References (22)

1. Hull, R.D., Raskob, G.E., Rosenbloom, D., Panju, A.A., Brill-Edwards, P.: Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N. Engl. J. Med. 323:830, 1990
2. Hull, R.D., Delmore, T., Genton, E., et al.: Warfarin sodium versus low dose heparin in the long term treatment of venous thrombosis. N. Engl. J. Med. 301:855, 1979
3. Whitfield, M.F.: Chondrodysplasia punctata after warfarin in early pregnancy. Arch. Dis. Child. 55:139, 1980
4. Stevenson, R., Burton, M., Ferlauto, G., Taylor, H.: Hazards of oral anticoagulants during pregnancy. J.A.M.A. 245:1549, 1980
5. Hull, R.D., Delmore, T., Carter, C., et al.: Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306:189, 1982
6. Hirsh, J , Levine, M: Low molecular weight heparin. Blood 79:1, 1992
7. Kakkar, V.V., Cohen, A.T., Edmondson, R.A., et al.: Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 341:259, 1993
8. Kakkar, V.V., Murray, W.J.G.: Efficacy and safety of low-molecular-weight-heparin (CY216) in preventing postoperative venous thromboembolism: a co-operative study. Br. J. Surg. 72:786, 1985
9. Nurmohamed, M.T., Rosendaal, F.R., Buller, H.R., et al.: Low molecular weight heparin versus heparin in general and orthopedic surgery: a meta-analysis. Lancet 340:152, 1992
10. Leizorovicz, A., Haugh, M.C., Chapuis, F-R., Samama, M.M., Boissel, J-P.: Low molecular weight heparin in prevention of perioperative thrombosis. B.M.J. 305:913, 1992
11. Prandoni, P., Lensing, A.W.A., Buller, H.R., et al.: Comparison of subcutaneous low-molecular-weight-heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 339:441, 1992
12. Vairel, E.G., Bouty-Boye, H., Toulemonde, F., Doutremepuich, C., Marsh, N.A., Gaffney, P J.: Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb. Res. 30:219, 1983
13. Forestier, F., Daffos, F., Capella-Pavlovsky, M.: Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy, study by direct fetal blood sampling under ultrasound. Thromb. Res. 34:557, 1984
14. Melissari, E., Das, S., Kanthou, C., Pemberton, K.D., Kakkar, V.V.: The use of LMW heparin in treating thromboembolism during pregnancy and prevention of osteopoiosis. Thromb. Haemost. 65:926, 1991
15. (R)) in patients with venous thromboembolism. Thromb. Haemost. 71:7, 1994
16. Westwick, J., Scully, M.F., Poll, C., Kakkar, V.V.: Comparison of the effects of low molecular weight heparin on activation of human platelets in vitro. Thromb. Res. 42:435, 1986
17. Warkentin, T.E., Levine, M.N., Hirsch, J., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332:1330, 1995
18. Leizorovicz, A., Simonncau, G., Decousus, H., Boissel, J.P.: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in the initial treatment of deep vein thrombosis: a meta-analysis. B.M.J. 309:299, 1994
19. Gallus, A.S., Jackaman, J., Tillett, J., Mills, W., Wycherley, A.: Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 6:1293, 1986
20. 125-fibrinogen test and phlebography in the diagnosis of deep vein thrombosis. Millbank Mem. Fund Q. 50:206, 1972
21. Valette, F., Hoffmeyer, U., Lloyd, A.: Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. Br J. Med. Econ. 8:111, 1995
22. Pinie, M., Aiello, S., Manotti, C., et al.: Low molecular weight heparin versus warfarin in the prevention of recurrence after deep vein thrombosis. Thromb. Haemost. 72:191, 1994